Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Business / Oculis OCS-01 trial failure, fraud...
Business securities fraud investigation

Oculis OCS-01 trial failure, fraud investigation

Analysis based on 43 articles · First reported May 29, 2026 · Last updated Jul 01, 2026

Sentiment
-70
Attention
6
Articles
43
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The failure of Oculis's lead drug candidate, OCS-01, in late-stage trials and the subsequent decision not to pursue FDA filing led to a significant 23.44% drop in Oculis's stock price. This event has triggered investigations by law firms like Pomerantz LLP and The Schall Law Firm into potential securities fraud, indicating a negative outlook for Oculis's stock and potential legal liabilities.

pharmaceuticals legal services
Event Summary

Oculis, a publicly traded company, announced on May 29, 2026, that its lead drug candidate, OCS-01, failed to meet the primary endpoint in two late-stage Phase 3 DIAMOND trials for diabetic macular edema. Following this announcement, Oculis's stock price fell by 23.44%. The company also stated it would not pursue an FDA filing for OCS-01 based on these results. This development has prompted investigations by law firms, including Pomerantz LLP and The Schall Law Firm, into whether Oculis engaged in securities fraud or other unlawful business practices by allegedly issuing false or misleading statements to investors regarding the trials' progress.

Key Actions
100 The Schall Law Firm announced investigation Oculis
96 Oculis announced topline results
95 Pomerantz LLP investigated claims Oculis
90 Oculis will not pursue filing United States — Food and Drug Administration
80 Riad Sherif claimed product works
60 Levi & Korsinsky initiated investigation Oculis
Entities Involved
priv
Oculis
Oculis is the subject of a securities fraud investigation by multiple law firms after its lead drug candidate, OCS-01, failed to meet primary endpoints in late-stage trials, causing a significant drop in its stock price. The company's decision not to pursue an FDA filing for OCS-01 further negatively impacts its market standing.
Importance 100.0 Sentiment -80.0
priv
Pomerantz LLP
Pomerantz LLP is investigating Oculis for potential securities fraud and unlawful business practices on behalf of investors. This firm is actively seeking investors to join a class action lawsuit.
Importance 80.0 Sentiment 20.0
priv
The Schall Law Firm
The Schall Law Firm is investigating Oculis for violations of securities laws, specifically focusing on whether the company issued false or misleading statements regarding its Phase 3 DIAMOND trials. The firm is encouraging affected shareholders to participate in the investigation.
Importance 80.0 Sentiment 20.0
per
Brian Schall
Brian Schall is the contact person at The Schall Law Firm for investors interested in discussing their rights regarding the investigation into Oculis.
Importance 60.0 Sentiment 30.0
per
Danielle Peyton
Danielle Peyton is a contact person at Pomerantz LLP for investors interested in joining the investigation against Oculis.
Importance 30.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration is the regulatory body that Oculis will not pursue a filing with for its drug candidate OCS-01, following the failed clinical trials.
Importance 30.0 Sentiment 0.0
Relationships
Oculis related ↔ United States — Food and Drug Administration
Pomerantz LLP competitor ↔ The Schall Law Firm Pomerantz LLP competes directly with The Schall Law Firm to secure lead plaintiff and counsel status in securities fraud
Pomerantz LLP related ↔ Brian Schall
Pomerantz LLP related ↔ Danielle Peyton
Pomerantz LLP related ↔ United States — Food and Drug Administration
The Schall Law Firm related ↔ Brian Schall
The Schall Law Firm related ↔ Danielle Peyton
The Schall Law Firm related ↔ United States — Food and Drug Administration
Brian Schall competitor ↔ Danielle Peyton Brian Schall operates as a professional competitor to Danielle Peyton within the securities litigation space. Both attor
Brian Schall related ↔ United States — Food and Drug Administration
Danielle Peyton related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.